NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: SUIC and VisionRenu MOU for AI Biotech and Precision Medicine
SUIC Worldwide and VisionRenu signed a strategic MOU to collaborate on AI biotechnology, precision medicine, and U.S. capital market expansion, aiming to accelerate VisionRenu's global growth and create long-term value in the multi-trillion-dollar AI biotech sector.
The MOU establishes a framework for collaboration in AI-powered biotechnology, precision medicine, and international capital market initiatives, aiming to accelerate VisionRenu's global expansion and create long-term value.
SUIC Worldwide Holdings Ltd. (OTC Markets: SUIC), a technology-enabled investment company, and VisionRenu Biomedical Technology Co., Ltd., a Taiwan-based medtech company specializing in brain health and ophthalmic devices.
The collaboration focuses on AI biotechnology, precision medicine, gene editing, DNA synthesis, and VisionRenu's MagRenu® TMS system for depression and ophthalmic laser technologies.
AI enables faster disease-gene discovery, improves CRISPR precision, and shortens therapeutic development cycles, with analysts expecting a multi-trillion-dollar market across healthcare, drug discovery, and synthetic biology.
It provides access to SUIC's U.S. capital market expertise, strategic financing, and international business development resources to accelerate commercialization of VisionRenu's medical devices.
The MagRenu® Transcranial Magnetic Stimulation (TMS) System, approved by Taiwan's TFDA for treating depression.
The agreement was announced on June 29, 2026.
SUIC is based in New York, NY, and VisionRenu is based in Taipei, Taiwan.
SUIC's partnership includes AI biotech startups supported by Taiwan's Ministry of Health and Welfare, positioning the company to expand into the AI biotech sector.
Visit their website at https://www.vision-renu.com/.